Finance

Lists
Why is ANW down 4.88%?
Dive Deeper
ANW:FRA
Immuron Ltd
€ 0.020
-4.88%
(-0.0010) 1D
10-р сарын 9, 22:00:00 (GMT+2)  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ANW...
Open
€ 0.02
High
€ 0.02
Low
€ 0.02
Mkt. cap
12.20 сая
Avg. vol.
627.00
Volume
0.00
52-wk high
€ 0.04
52-wk low
€ 0.01
No. of employees
8
Open
€ 0.02
High
€ 0.02
Low
€ 0.02
Mkt. cap
12.20 сая
Avg. vol.
627.00
Volume
0.00
52-wk high
€ 0.04
52-wk low
€ 0.01
No. of employees
8
News stories
From web sources and news partners
Profile
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited. Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment. In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
About Immuron Ltd
CEO-
Employees8
Founded1994
HeadquartersBlackburn North, Викториа, Австрали
Sector-
Previous reportsAll values in AUD
Loading Previous Earnings...
Revenue
Net income
All values in AUD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
2.09 сая
2.09 сая
1.76 сая
1.76 сая
Cost of goods sold
765.33 мян
765.33 мян
603.93 мян
603.93 мян
Cost of revenue
765.33 мян
765.33 мян
603.93 мян
603.93 мян
Research and development expenses
589.74 мян
589.74 мян
376.98 мян
376.98 мян
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.89 сая
1.89 сая
2.00 сая
2.00 сая
Operating expense
2.31 сая
2.31 сая
1.96 сая
1.96 сая
Total operating expenses
3.08 сая
3.08 сая
2.56 сая
2.56 сая
Operating income
-986.57 мян
-986.57 мян
-796.24 мян
-796.24 мян
Other non operating income
-
-
-
-
EBT including unusual items
-959.54 мян
-959.54 мян
-880.46 мян
-880.46 мян
EBT excluding unusual items
-959.54 мян
-959.54 мян
-880.46 мян
-880.46 мян
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-167.08 мян
-167.08 мян
-417.86 мян
-417.86 мян
Net income
-959.54 мян
-959.54 мян
-880.46 мян
-880.46 мян
Net profit margin
-45.86%
-45.86%
-49.90%
-49.90%
Earnings per share
-
-
-
-
Interest and investment income
30.32 мян
30.32 мян
62.40 мян
62.40 мян
Interest expense
-3.29 мян
-3.29 мян
-4.06 мян
-4.06 мян
Net interest expenses
27.03 мян
27.03 мян
58.33 мян
58.33 мян
Depreciation and amortization charges
-
-
-
-
EBITDA
-974.15 мян
-974.15 мян
-783.82 мян
-785.66 мян
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google аппс